Oncotarget

Research Papers:

Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380

Xiao Huang, Mengru Cao, Li Wang, Shuhong Wu, Xiaoying Liu, Hongyu Li, Hui Zhang, Rui-Yu Wang, Xiaoping Sun, Caimiao Wei, Keith A. Baggerly, Jack A. Roth, Michael Wang, Stephen G. Swisher and Bingliang Fang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:345-354. https://doi.org/10.18632/oncotarget.2814

Metrics: PDF 1456 views  |   HTML 2182 views  |   ?  


Abstract

Xiao Huang1,*, Mengru Cao1,7,*, Li Wang1, Shuhong Wu1, Xiaoying Liu1, Hongyu Li1, Hui Zhang1, Rui-Yu Wang2, Xiaoping Sun3, Caimiao Wei4, Keith A. Baggerly5, Jack A. Roth1, Michael Wang6, Stephen G. Swisher1 and Bingliang Fang1

1 Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

2 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

3 Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

4 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

5 Department of Bioinformatics and Computation Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

6 Department of Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

7 The Fourth Department of Medicine Oncology, Harbin Medical University Cancer Hospital, Harbin, China

* These authors contributed equally to this work

Correspondence:

Bingliang Fang, email:

Keywords: Cancer, drug development, biomarker, sulfotransferase, SULT1A1, personalized therapy

Received: September 05, 2014 Accepted: November 15, 2014 Published: November 16, 2014

Abstract

The small molecule anticancer agent NSC-743380 modulates functions of multiple cancer-related pathways and is highly active in a subset of cancer cell lines in the NCI-60 cell line panel. It also has promising in vivo anticancer activity. However, the mechanisms underlying NSC-743380’s selective anticancer activity remain uncharacterized. To determine biomarkers that may be used to identify responders to this novel anticancer agent, we performed correlation analysis on NSC-743380’s anticancer activity and the gene expression levels in NCI-60 cell lines and characterized the functions of the top associated genes in NSC-743380–mediated anticancer activity. We found sulfotransferase SULT1A1 is causally associated with NSC-743380’s anticancer activity. SULT1A1 was expressed in NSC-743380–sensitive cell lines but was undetectable in resistant cancer cells. Ectopic expression of SULT1A1 in NSC743380 resistant cancer cells dramatically sensitized the resistant cells to NSC-743380. Knockdown of the SULT1A1 in the NSC-743380 sensitive cancer cell line rendered it resistance to NSC-743380. The SULT1A1 protein levels in cell lysates from 18 leukemia cell lines reliably predicted the susceptibility of the cell lines to NSC-743380. Thus, expression of SULT1A1 in cancer cells is required for NSC-743380’s anticancer activity and can be used as a biomarker for identification of NSC-743380 responders.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2814